 |
18 Diseases |  |
0 Trials |
|
0 Trials |  |
29 News |  |
- | mericitabine (RG7128) / Gilead, Roche, Sovaldi (sofosbuvir) / Gilead
Journal: Resistance to excision determines efficiency of inhibition of hepatitis C virus RNA-dependent RNA polymerase by nucleotide analogs including sofosbuvir. (Pubmed Central) - Jan 14, 2021
In contrast, although UMP analogs weremore slowly incorporated, UMP excision was alsoslow and inefficient, and modifications to the 2'Cof the UTP ribose ring further decreased excisionrates to an undetectable level. Taken together, theseresults suggest that the greater clinical effectivenessof the UMP analog sofosbuvir is largely due to itbeing intractable to nucleotide-mediated excisioncompared with similar NAs such as mericitabine.
- | Ganovo (danoprevir) / Roche, Ascletis, Pfizer, mericitabine (RG7128) / Gilead, Roche
Trial completion: A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Na (clinicaltrials.gov) - Nov 4, 2014
P2, N=43, Completed, Sponsor: Hoffmann-La Roche
Taken together, theseresults suggest that the greater clinical effectivenessof the UMP analog sofosbuvir is largely due to itbeing intractable to nucleotide-mediated excisioncompared with similar NAs such as mericitabine. Active, not recruiting --> Completed
- |||| Ganovo (danoprevir) / Roche, Ascletis, Pfizer, mericitabine (RG7128) / Gilead, Roche
Trial completion, Trial primary completion date, Combination therapy: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Na (clinicaltrials.gov) - Nov 4, 2014
P2, N=170, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Oct 2012
- Trial primary completion date, Combination therapy: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment (clinicaltrials.gov) - Jul 23, 2014
P2, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Oct 2012 Trial primary completion date: Jul 2014 --> Mar 2014
- |||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche, Victrelis (boceprevir) / Roche, Merck (MSD)
Trial completion, Combination therapy: A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C (clinicaltrials.gov) - Feb 23, 2014
P2, N=58, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jul 2014 --> Mar 2014 Active, not recruiting --> Completed
- |||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
Trial completion, Combination therapy: A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C (clinicaltrials.gov) - Feb 23, 2014
P2, N=80, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || mericitabine (RG7128) / Gilead, Roche
Enrollment change: A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers (clinicaltrials.gov) - Jan 19, 2014
P1, N=97, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=65 --> 97
- |||| Trial completion: ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Na (clinicaltrials.gov) - Jan 12, 2014
P2, N=110, Completed, Sponsor: Hoffmann-La Roche
N=65 --> 97 Active, not recruiting --> Completed
- ||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
Enrollment change, Combination therapy: A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C (clinicaltrials.gov) - Oct 20, 2013
P2, N=80, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=120 --> 80
- ||| Enrollment change: ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Na (clinicaltrials.gov) - Jun 17, 2013
P2, N=110, Completed, Sponsor: Hoffmann-La Roche
N=120 --> 80 N=180 --> 110
- |||| Ganovo (danoprevir) / Roche, Ascletis, Pfizer, Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
Trial completion, Combination therapy: A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C (clinicaltrials.gov) - Mar 24, 2013
P2, N=381, Completed, Sponsor: Hoffmann-La Roche
N=180 --> 110 Active, not recruiting --> Completed
- | Ganovo (danoprevir) / Roche, Ascletis, Pfizer, mericitabine (RG7128) / Gilead, Roche
Enrollment closed: A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Na (clinicaltrials.gov) - Mar 3, 2013
P2, N=43, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
Enrollment change, Combination therapy: A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 (clinicaltrials.gov) - Sep 18, 2012
P2, N=168, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting N=168168 --> 168
- ||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
Enrollment change, Combination therapy: A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 (clinicaltrials.gov) - Sep 18, 2012
P2, N=413, Completed, Sponsor: Hoffmann-La Roche
N=168168 --> 168 N=413413 --> 413
- Trial withdrawal, Combination therapy: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment (clinicaltrials.gov) - Sep 4, 2012
P2, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
N=413413 --> 413 Not yet recruiting --> Withdrawn
- Enrollment change, Combination therapy: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment (clinicaltrials.gov) - Sep 4, 2012
P2, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Withdrawn N=100 --> 0
- |||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
Trial completion, Combination therapy: A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 (clinicaltrials.gov) - Aug 26, 2012
P2, N=413, Completed, Sponsor: Hoffmann-La Roche
N=100 --> 0 Active, not recruiting --> Completed
- |||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
Trial completion, Combination therapy: A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 (clinicaltrials.gov) - Aug 21, 2012
P2, N=168, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P2 trial: ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Na (clinicaltrials.gov) - Jun 24, 2012
P2, N=110, Completed, Sponsor: Hoffmann-La Roche
- New P2 trial, Combination therapy: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment (clinicaltrials.gov) - Apr 15, 2012
P2, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
- ||| Ganovo (danoprevir) / Roche, Ascletis, Pfizer, mericitabine (RG7128) / Gilead, Roche
Enrollment closed, Combination therapy: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Na (clinicaltrials.gov) - Mar 15, 2012
P2, N=170, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Ganovo (danoprevir) / Roche, Ascletis, Pfizer, mericitabine (RG7128) / Gilead, Roche
New P2 trial: A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Na (clinicaltrials.gov) - Nov 29, 2011
P2, N=43, Active, not recruiting, Sponsor: Hoffmann-La Roche
- ||||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche, Victrelis (boceprevir) / Roche, Merck (MSD)
New P2 trial, Combination therapy: A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C (clinicaltrials.gov) - Nov 28, 2011
P2, N=58, Completed, Sponsor: Hoffmann-La Roche
- ||||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
New P2 trial, Combination therapy: A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C (clinicaltrials.gov) - Nov 28, 2011
P2, N=80, Completed, Sponsor: Hoffmann-La Roche